| Literature DB >> 25261724 |
Sai Hari A Gandham1, David E Volk2, Ganesh L R Lokesh2, Muniasamy Neerathilingam1, David G Gorenstein3.
Abstract
Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM. Published by Elsevier Inc.Entities:
Keywords: Anti-viral; Dengue virus; Diagnostic agent; Envelope protein; SELEX; Thioaptamer
Mesh:
Substances:
Year: 2014 PMID: 25261724 PMCID: PMC4272640 DOI: 10.1016/j.bbrc.2014.09.053
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575